Nanoform Finland Plc (NANOFH) - Total Liabilities
Based on the latest financial reports, Nanoform Finland Plc (NANOFH) has total liabilities worth €12.56 Million EUR (≈ $14.68 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore NANOFH year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Nanoform Finland Plc - Total Liabilities Trend (2016–2024)
This chart illustrates how Nanoform Finland Plc's total liabilities have evolved over time, based on quarterly financial data.
Nanoform Finland Plc Competitors by Total Liabilities
The table below lists competitors of Nanoform Finland Plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Asetek A/S
F:A31
|
Germany | €35.78 Million |
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
USA | $7.56 Million |
|
Mediaco Holding Inc
NASDAQ:MDIA
|
USA | $244.74 Million |
|
Rein Therapeutics Inc
NASDAQ:RNTX
|
USA | $14.70 Million |
|
Axon Partners Group S.A.
MC:APG
|
Spain | €6.70 Million |
|
Asia Pacific Satellite Inc
KQ:211270
|
Korea | ₩22.41 Billion |
|
Cheer Time Enterprise Co Ltd
TW:3229
|
Taiwan | NT$210.89 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Nanoform Finland Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Nanoform Finland Plc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nanoform Finland Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nanoform Finland Plc (2016–2024)
The table below shows the annual total liabilities of Nanoform Finland Plc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €11.77 Million ≈ $13.77 Million |
+5.24% |
| 2023-12-31 | €11.19 Million ≈ $13.08 Million |
-16.69% |
| 2022-12-31 | €13.43 Million ≈ $15.70 Million |
-9.63% |
| 2021-12-31 | €14.86 Million ≈ $17.37 Million |
+32.07% |
| 2020-12-31 | €11.25 Million ≈ $13.15 Million |
+126.01% |
| 2019-12-31 | €4.98 Million ≈ $5.82 Million |
+56.78% |
| 2018-12-31 | €3.18 Million ≈ $3.71 Million |
+205.34% |
| 2017-12-31 | €1.04 Million ≈ $1.22 Million |
+82.31% |
| 2016-12-31 | €570.41K ≈ $666.87K |
-- |
About Nanoform Finland Plc
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) na… Read more